MT-026 / Suzhou Maximum Bio-tech - LARVOL DELTA

T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors (PRNewswire) - "...In addition to MT027, T-MAXIMUM is advancing two other allogeneic CAR-T cell therapy candidates: MT026 and MT020. MT026 targets IL13Rα2 and is being developed for the treatment of solid tumors....MT020 is being developed to treat B-cell related autoimmune diseases."

Pipeline update • Immunology • Solid Tumor

Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma (clinicaltrials.gov) - P=N/A | N=12 | Recruiting | Sponsor: Second Affiliated Hospital of Soochow University

CAR T-Cell Therapy • Metastases • New trial • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • CD276 • PD-L1